aTyr Pharma (ATYR) Competitors $4.70 -0.02 (-0.42%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.73 +0.03 (+0.72%) As of 08/1/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATYR vs. CNTA, VCEL, CGON, DNLI, BLTE, OCUL, KNSA, APGE, ARQT, and IMCRShould you be buying aTyr Pharma stock or one of its competitors? The main competitors of aTyr Pharma include Centessa Pharmaceuticals (CNTA), Vericel (VCEL), CG Oncology (CGON), Denali Therapeutics (DNLI), Belite Bio (BLTE), Ocular Therapeutix (OCUL), Kiniksa Pharmaceuticals International (KNSA), Apogee Therapeutics (APGE), Arcutis Biotherapeutics (ARQT), and Immunocore (IMCR). These companies are all part of the "pharmaceutical products" industry. aTyr Pharma vs. Its Competitors Centessa Pharmaceuticals Vericel CG Oncology Denali Therapeutics Belite Bio Ocular Therapeutix Kiniksa Pharmaceuticals International Apogee Therapeutics Arcutis Biotherapeutics Immunocore Centessa Pharmaceuticals (NASDAQ:CNTA) and aTyr Pharma (NASDAQ:ATYR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability. Do insiders & institutionals hold more shares of CNTA or ATYR? 82.0% of Centessa Pharmaceuticals shares are held by institutional investors. Comparatively, 61.7% of aTyr Pharma shares are held by institutional investors. 7.1% of Centessa Pharmaceuticals shares are held by company insiders. Comparatively, 3.7% of aTyr Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has higher earnings and valuation, CNTA or ATYR? aTyr Pharma has lower revenue, but higher earnings than Centessa Pharmaceuticals. Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than aTyr Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCentessa Pharmaceuticals$6.85M327.91-$235.76M-$1.81-9.29aTyr Pharma$230K1,818.70-$64.02M-$0.81-5.80 Which has more risk & volatility, CNTA or ATYR? Centessa Pharmaceuticals has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, aTyr Pharma has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500. Is CNTA or ATYR more profitable? Centessa Pharmaceuticals' return on equity of -40.22% beat aTyr Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Centessa PharmaceuticalsN/A -40.22% -29.95% aTyr Pharma N/A -87.09%-64.77% Does the media refer more to CNTA or ATYR? In the previous week, Centessa Pharmaceuticals had 5 more articles in the media than aTyr Pharma. MarketBeat recorded 11 mentions for Centessa Pharmaceuticals and 6 mentions for aTyr Pharma. aTyr Pharma's average media sentiment score of 0.94 beat Centessa Pharmaceuticals' score of 0.93 indicating that aTyr Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Centessa Pharmaceuticals 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive aTyr Pharma 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer CNTA or ATYR? Centessa Pharmaceuticals currently has a consensus price target of $28.10, suggesting a potential upside of 67.16%. aTyr Pharma has a consensus price target of $20.20, suggesting a potential upside of 329.79%. Given aTyr Pharma's stronger consensus rating and higher possible upside, analysts plainly believe aTyr Pharma is more favorable than Centessa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Centessa Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 3.00aTyr Pharma 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 SummaryCentessa Pharmaceuticals and aTyr Pharma tied by winning 8 of the 16 factors compared between the two stocks. Get aTyr Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATYR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATYR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATYR vs. The Competition Export to ExcelMetricaTyr PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$420.10M$2.99B$5.49B$9.54BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-5.8017.7428.8623.83Price / Sales1,818.70178.75371.4866.02Price / CashN/A41.9535.4557.96Price / Book5.668.508.275.54Net Income-$64.02M-$55.06M$3.25B$259.28M7 Day Performance-19.38%-3.99%-3.73%-4.68%1 Month Performance-10.98%9.58%4.29%4.36%1 Year Performance156.83%6.70%25.87%17.89% aTyr Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATYRaTyr Pharma2.6028 of 5 stars$4.70-0.4%$20.20+329.8%+141.0%$420.10M$230K-5.8053Options VolumeGap UpCNTACentessa Pharmaceuticals3.2078 of 5 stars$15.20-1.4%$28.10+84.9%+63.4%$2.06B$6.85M-8.40200News CoverageAnalyst ForecastInsider TradeVCELVericel2.0999 of 5 stars$41.45+3.3%$61.14+47.5%-25.0%$2.02B$237.22M1,382.13300Trending NewsEarnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionCGONCG Oncology1.9211 of 5 stars$25.86-0.9%$55.30+113.8%-22.3%$1.99B$1.14M-17.1361News CoverageGap DownDNLIDenali Therapeutics4.5811 of 5 stars$13.63-0.3%$33.71+147.4%-42.4%$1.99B$330.53M-5.10430News CoverageUpcoming EarningsBLTEBelite Bio2.1729 of 5 stars$62.05-0.3%$96.67+55.8%+35.4%$1.98BN/A-45.6310News CoverageUpcoming EarningsOCULOcular Therapeutix3.6107 of 5 stars$12.08-1.1%$17.33+43.5%+47.7%$1.95B$63.72M-10.50230Upcoming EarningsKNSAKiniksa Pharmaceuticals International3.1521 of 5 stars$27.04+2.7%$39.67+46.7%+24.1%$1.92B$423.24M-108.16220News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionAPGEApogee Therapeutics2.4768 of 5 stars$39.66-2.8%$99.00+149.6%-17.5%$1.88BN/A-11.0291Positive NewsARQTArcutis Biotherapeutics2.7194 of 5 stars$14.96+0.7%$19.40+29.7%+50.7%$1.77B$196.54M-14.38150News CoverageUpcoming EarningsIMCRImmunocore1.7414 of 5 stars$33.94-3.5%$58.89+73.5%-16.7%$1.77B$310.20M-78.93320News CoverageUpcoming Earnings Related Companies and Tools Related Companies Centessa Pharmaceuticals Alternatives Vericel Alternatives CG Oncology Alternatives Denali Therapeutics Alternatives Belite Bio Alternatives Ocular Therapeutix Alternatives Kiniksa Pharmaceuticals International Alternatives Apogee Therapeutics Alternatives Arcutis Biotherapeutics Alternatives Immunocore Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATYR) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding aTyr Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share aTyr Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATYR Stock Alerts